Figure 1 | Laboratory Investigation

Figure 1

From: Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin

Figure 1

Circulating antithrombin in MM patients (N=7) treated with bortezomib. (a) Time-dependent effects of bortezomib on the plasma antigen and anti-FXa anticoagulant function levels. (b) Representative blots of both, native (Nat) and latent (Lat) antithrombin as revealed by native-PAGE without (native) or with 6 M urea (latent) and immunoblotting. Levels of the latent circulating form of antithrombin were quantified by optical densitometry of the gels. Results are presented as percentages of their baseline levels as means±s.e.m. (**P<0.01; ***P<0.001).

Back to article page